Metastatic Head and Neck Cancer Clinical Trials

20 clinical trials for Metastatic Head and Neck Cancer across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC — RECRUITING · PHASE2
• A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 — RECRUITING · PHASE2
• Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer — RECRUITING · PHASE1
• Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. — RECRUITING · PHASE2
• Effects of Infusion Timing on Treatment Response in Solid Tumors — NOT_YET_RECRUITING · PHASE2
• Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE3
• Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC — COMPLETED · PHASE2
• Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC — COMPLETED · PHASE2
• Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers — ACTIVE_NOT_RECRUITING · NA
• A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) — COMPLETED · PHASE3
• Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors — TERMINATED · PHASE1
• A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers — COMPLETED · PHASE1
• Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) — OTHER · PHASE1
• BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) — TERMINATED · PHASE2
• Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer — TERMINATED · PHASE2
• Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) — OTHER · NA
• A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes — COMPLETED · PHASE2
• Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers — WITHDRAWN · PHASE2
• Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer — TERMINATED · PHASE3

Refine this search